Cargando…
Drug target ranking for glioblastoma multiforme
BACKGROUND: Glioblastoma Multiforme, an aggressive primary brain tumor, has a poor prognosis and no effective standard of care treatments. Most patients undergoing radiotherapy, along with Temozolomide chemotherapy, develop resistance to the drug, and recurrence of the tumor is a common issue after...
Autores principales: | Saraf, Radhika, Agah, Shaghayegh, Datta, Aniruddha, Jiang, Xiaoqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074458/ https://www.ncbi.nlm.nih.gov/pubmed/33902757 http://dx.doi.org/10.1186/s42490-021-00052-w |
Ejemplares similares
-
Human Endogenous Retroviruses in Glioblastoma Multiforme
por: Yuan, Zihao, et al.
Publicado: (2021) -
Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme
por: Lim, Xin Yuan, et al.
Publicado: (2023) -
Targeted Nanotechnology in Glioblastoma Multiforme
por: Glaser, Talita, et al.
Publicado: (2017) -
Drug repurposing for the treatment of glioblastoma multiforme
por: Abbruzzese, Claudia, et al.
Publicado: (2017) -
Targeting cellular pathways in glioblastoma multiforme
por: Pearson, Joshua R D, et al.
Publicado: (2017)